Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: 135(10)
Published: May 14, 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) is rising among reproductive-aged individuals and in pregnancy. MASLD pregnancy does increase such risks as gestational diabetes, preeclampsia, preterm birth. Although routine screening for has not been established pregnancy, with metabolic comorbidities, type 2 diabetes mellitus, should be evaluated by imaging panel. Preconception counseling address potential well need optimized health before during Fibrosis assessment ideally completed to identify cases of cirrhosis that may warrant additional preconception management, variceal screening, comanagement maternal-fetal medicine specialists. In patients MASLD, aspirin advised at 12 weeks age lower preeclampsia risk. the absence cirrhosis, no blood test monitoring needed. general population, breastfeeding beneficial effects on birthing parents offspring thus encouraged setting including access enhanced lactation support. Research needs include evaluation long-term infants, safety data MASLD-directed therapies lactation.
Language: Английский